92587-68-3

Basic information

• Product Name: 3-Butyn-1-ol, 4-(3-methoxyphenyl)-
• CAS NO: 92587-68-3
• Molecular Formula: C11H12O2
• Molecular Weight: 176.215
• Mol File: 92587-68-3.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 3-Butyn-1-ol, 4-(3-methoxyphenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Butyn-1-ol, 4-(3-methoxyphenyl)-(92587-68-3)
• EPA Substance Registry System: 3-Butyn-1-ol, 4-(3-methoxyphenyl)-(92587-68-3)

Safety Data

• Hazardous Substances Data: 92587-68-3(Hazardous Substances Data)

Upstream product

• 2398-37-0 3-methoxyphenyl bromide 
• 927-74-2 3-Butyn-1-ol 
• 766-85-8 3-methoxy-1-iodobenzene 

Downstream Products

• 1374024-12-0 diethyl 5-(1-(3-methoxyphenyl)but-3-enyl)-3,4-dihydro-2H-pyrrole-2,2-dicarboxylate 
• 1374024-01-7 diethyl 2-(allylamino)-2-(4-(3-methoxyphenyl)but-3-ynyl)malonate 
• 1337989-68-0 1-(2-benzofuranylmethyl)-4-[4-(3-methoxyphenyl)butyl]piperazine 
• 1280640-17-6 C₁₃H₁₁NO₃ 
• 160360-51-0 (R)-6-(3-Methoxy-phenyl)-hex-1-yn-3-ol 
• 91152-86-2 4-(3'-methoxyphenyl)butyraldehyde 
• 557786-37-5 [4-(3-methoxyphenyl)butyl]methylcarbamic acid tert-butyl ester 

Relevant articles and documents

GLYCOSIDE COMPOUND AND PREPARATION METHOD THEREFOR, COMPOSITION, APPLICATION, AND INTERMEDIATE

The present invention discloses a glycoside compound represented by Formula III, and a preparation method, a composition, use and an intermediate thereof. The glycoside compound provided in the present invention has simple preparation method, can significantly increase the expression of VEGF-A mRNA, and is effective in promoting the angiogenesis. This provides a reliable guarantee for the development of drugs with pro-angiogenic activity for treating cerebral infarction cerebral stroke, myocardial infarction, and ischemic microcirculatory disturbance of lower limbs.

Targeting an Aromatic Hotspot in Plasmodium falciparum 1-Deoxy-d-xylulose-5-phosphate Reductoisomerase with β-Arylpropyl Analogues of Fosmidomycin

Blocking the 2-C-methyl-d-erythrithol-4-phosphate pathway for isoprenoid biosynthesis offers new ways to inhibit the growth of Plasmodium spp. Fosmidomycin [(3-(N-hydroxyformamido)propyl)phosphonic acid, 1] and its acetyl homologue FR-900098 [(3-(N-hydroxyacetamido)propyl)phosphonic acid, 2] potently inhibit 1-deoxy-d-xylulose-5-phosphate reductoisomerase (Dxr), a key enzyme in this biosynthetic pathway. Arylpropyl substituents were introduced at the β-position of the hydroxamate analogue of 2 to study changes in lipophilicity, as well as electronic and steric properties. The potency of several new compounds on the P. falciparum enzyme approaches that of 1 and 2. Activities against the enzyme and parasite correlate well, supporting the mode of action. Seven X-ray structures show that all of the new arylpropyl substituents displace a key tryptophan residue of the active-site flap, which had made favorable interactions with 1 and 2. Plasticity of the flap allows substituents to be accommodated in many ways; in most cases, the flap is largely disordered. Compounds can be separated into two classes based on whether the substituent on the aromatic ring is at the meta or para position. Generally, meta-substituted compounds are better inhibitors, and in both classes, smaller size is linked to better potency.

Effects of linker elongation in a series of N-(2-benzofuranylmethyl)- N′-(methoxyphenylalkyl)piperazine σ1 receptor ligands

In our continued exploration of disubstituted piperazine derivatives as sigma (σ) receptor ligands with central nervous system (CNS) activity, a series of N-(2-benzofuranylmethyl)-N′-(methoxyphenylalkyl)piperazines (16-21 and 26-31) were synthesized, anti